Patenting stem cell therapies in the US: The role and risks of product-by-process claims (Restem v Jadi cell)
Patenting stem cell therapies in the US is a difficult business, especially if your cell therapy product is defined solely by natural surfac...
Dr Rose Hughes -
Sunday, March 29, 2026
Patenting stem cell therapies in the US: The role and risks of product-by-process claims (Restem v Jadi cell)
Reviewed by Dr Rose Hughes
on
Sunday, March 29, 2026
Rating:
Reviewed by Dr Rose Hughes
on
Sunday, March 29, 2026
Rating: